Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Supernus Pharmaceuticals, Inc.
organization5 mentionslast seen Nov 2, 2026
Pharmaceutical company merging with Indivior.
Relationships 22
- Supernus Pharmaceuticals, Inc.commercializesONAPGO99% confidence2 sources
- Supernus Pharmaceuticals, Inc.commercializesQelbree99% confidence2 sources
- Supernus Pharmaceuticals, Inc.commercializesSUBLOCADE99% confidence2 sources
- Supernus Pharmaceuticals, Inc.commercializesGOCOVRI99% confidence2 sources
- Indivior Pharmaceuticals, Inc.acquiresSupernus Pharmaceuticals, Inc.99% confidence2 sources
- Supernus Pharmaceuticals, Inc.employsJack Khattar99% confidence2 sources
- Indivior Pharmaceuticals, Inc.acquiresSupernus Pharmaceuticals, Inc.99% confidence2 sources
- Supernus Pharmaceuticals, Inc.commercializesZURZUVAE99% confidence2 sources
- Supernus Pharmaceuticals, Inc.employsTimothy C. Dec97% confidence1 source
- Supernus Pharmaceuticals, Inc.employsTony Kingsley97% confidence1 source
- Supernus Pharmaceuticals, Inc.funded byMerger financing96% confidence1 source
- Supernus Pharmaceuticals, Inc.employsJack A. Khattar96% confidence1 source
- Supernus Pharmaceuticals, Inc.employsPadmanabh Bhatt96% confidence1 source
- Supernus Pharmaceuticals, Inc.employsTodd Horich96% confidence1 source
- Supernus Pharmaceuticals, Inc.employsFrank Mottola96% confidence1 source
- Supernus Pharmaceuticals, Inc.employsTimothy C. Dec96% confidence1 source
- Supernus Pharmaceuticals, Inc.employsBryan Roecklein96% confidence1 source
- Supernus Pharmaceuticals, Inc.employsJonathan Rubin96% confidence1 source
- Supernus Pharmaceuticals, Inc.funded byTerm Loan Facility95% confidence1 source
- Citibank, N.A.suppliesSupernus Pharmaceuticals, Inc.93% confidence1 source
- Supernus Pharmaceuticals, Inc.applies tocentral nervous system disease treatment93% confidence1 source
- Supernus Pharmaceuticals, Inc.developsONAPGO85% confidence1 source
Relationship
Supernus Pharmaceuticals, Inc.commercializesZURZUVAE
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 2, 2026SUPERNUS PHARMACEUTICALS, INC. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.01: Completion of Acquisition or Disposition of Assets; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 3.03: Material Modifications to Rights of Security Holders; Item 5.01: Changes in Control of Registrant; Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
An 11-product portfolio spans opioid use disorder, psychiatry, and neurology, and includes five core growth drivers – SUBLOCADE®, Qelbree®, GOCOVRI®, ONAPGO®, and ZURZUVAE®
- filingSEC EDGARNov 2, 2026Indivior Pharmaceuticals, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.01: Completion of Acquisition or Disposition of Assets; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
five core growth drivers – SUBLOCADE®, Qelbree®, GOCOVRI®, ONAPGO®, and ZURZUVAE®